Why the study?
Does the curcumin analog C66 prevent high glucose-induced inflammation and diabetic cardiomyopathy in preclinical models?
Population
H9c2 cells, neonatal cardiomyocytes, and mice with type 1 diabetes
Comparison
C66 or SP600125 at 5 mg/kg vs Untreated high glucose conditions or untreated…
Design
Preclinical
Authors
Loading...
Supports JNK inhibition as a target in diabetic cardiomyopathy models; leaves open translation to human therapy.
Does the curcumin analog C66 prevent high glucose-induced inflammation and diabetic cardiomyopathy in preclinical models?
The novel curcumin analog C66 protects against diabetic cardiomyopathy by inhibiting JNK phosphorylation, reducing inflammation and apoptosis.
Pan et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: